Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Not Confirmed
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Industry Trade Show
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
01 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/altos-biologics-files-approval-of-aflibercept-biosimilar-302186707.html
Details:
ALT-L9 (aflibercept), biosimilar of Eylea, is a recombinant fusion protein which inhibits VEGF A. It is being evaluated in phase 3 clinical studies for the treatment of Neovascular (Wet) AMD.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Brand Name: ALT-L9
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2024
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Altos Biologics Files for Approval of Aflibercept Biosimilar
Details : ALT-L9 (aflibercept), biosimilar of Eylea, is a recombinant fusion protein which inhibits VEGF A. It is being evaluated in phase 3 clinical studies for the treatment of Neovascular (Wet) AMD.
Brand Name : ALT-L9
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 01, 2024
Details:
ALT-L9 (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Brand Name: ALT-L9
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Lead Product(s) : Aflibercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : ALT-L9 (aflibercept) is a vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy.
Brand Name : ALT-L9
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 22, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?